Telemedicine rheumatology in the United States — dramatically expanded by COVID-19 telehealth regulatory flexibilities and permanently retained through legislative action — is transforming AS care delivery by extending specialist reach, improving treatment adherence, and enabling between-visit disease activity monitoring that traditional clinic-only care models cannot provide, with the US Sacroiliitis Treatment Market reflecting telemedicine's growing role in American AS management.

CMS telehealth coverage permanence — with the Infrastructure Investment and Jobs Act and other legislation making certain COVID-era telehealth flexibilities permanent for Medicare beneficiaries — provides the sustainable reimbursement framework that US rheumatology practices need to maintain telemedicine infrastructure investment. State insurance mandate laws increasingly requiring commercial insurer telehealth coverage parity with in-person services extend telemedicine coverage beyond Medicare to commercially insured AS patients.

Telemedicine AS monitoring programs — US rheumatology practices implementing regular BASDAI or ASDAS video visit assessments between quarterly in-person appointments — provide the treat-to-target monitoring frequency that AS management benefits from without requiring AS patients to take time from work for every monitoring interaction. The combination of biannual comprehensive in-person assessment with quarterly telemedicine monitoring visits matches the disease activity surveillance intensity that T2T AS management requires.

Digital health integration with telemedicine AS care — wearable activity monitors, electronic PRO platforms, and home-based laboratory testing enabling laboratory monitoring without clinic visits — is creating the comprehensive remote AS management infrastructure that approaches in-person clinic care quality while dramatically reducing patient access burden for stable AS patients requiring regular monitoring rather than active treatment adjustment.

Do you think US telemedicine infrastructure investment during COVID has created a permanent transformation in AS care delivery that will continue improving AS patient outcomes through more frequent monitoring and earlier treatment adjustment?

FAQ

How does telemedicine benefit US AS patients? Telemedicine reduces travel burden for rural AS patients lacking local rheumatologists, enables more frequent disease activity monitoring between in-person visits, improves biologic adherence through regular check-ins, and allows rapid assessment of disease flares without requiring urgent in-person appointments.

Is telemedicine rheumatology reimbursed by Medicare? Medicare permanently covers audio-video telemedicine visits for established rheumatology patients following COVID-era telehealth expansion legislation; telemedicine reimbursement for AS monitoring visits is available under standard evaluation and management codes for video visits meeting CMS documentation requirements.

#USSacroiliitis #UStelermedicineAS #TelemedicineRheumatologyUS #RemoteASmonitoring #DigitalAScare #AmericanRheumatologyDigital